The estrogen component in Yasmin is ethinyl estradiol. Ethinyl estradiol is a synthetic estrogen used in many combined oral contraceptives; it provides endometrial stabilization and, by supplying negative feedback to the hypothalamic-pituitary axis, helps suppress ovulation. Yasmin pairs this estrogen with drospirenone, a progestin that adds ovulation suppression and changes in cervical mucus and the endometrium. The other options mix up this role: drospirenone is the progestin, not the estrogen; saying ethinyl estradiol is a progestin is incorrect; and levonorgestrel is another progestin used in different formulations.

Understanding the question hinges on the difference between a cure and a disease-modifying therapy. Ocrelizumab targets CD20-positive B cells to dampen the autoimmune attack on myelin, which reduces relapse rates and slows disability progression in both relapsing-remitting MS and primary progressive MS. This proves its effectiveness at controlling disease activity, but it does not eradicate MS or permanently restore lost neurological function. MS remains a chronic condition that can reactivate if therapy is stopped, and no treatment has been proven to cure the disease. So, while ocrelizumab can significantly reduce activity and progression, it is not a cure.

During sensitization, helper T cells polarize to a TH2 profile and drive B lymphocytes to switch to producing IgE antibodies. These allergen-specific IgE molecules then bind to high-affinity receptors on mast cells and basophils, flagging them for later response. This sets up the sensitized state: upon re-exposure, the allergen cross-links the bound IgE, triggering mast cell degranulation and release of mediators like histamine that cause symptoms. So the sequence described—TH2 cells signaling B cells to produce antibodies that attach to mast cells—fits the sensitization stage precisely. The other ideas describe events that don’t occur during sensitization: immediate symptoms from first exposure, direct histamine release without prior sensitization, or involvement of cytotoxic T cells, which isn’t the hallmark of this process.

Glucagon is the signal that drives hepatic glucose output. It acts on liver cells to raise blood glucose by stimulating both glycogen breakdown and glucose production through gluconeogenesis. In obesity, insulin resistance reduces the liver’s responsiveness to insulin, so insulin’s usual suppression of hepatic glucose production is diminished. This makes the glucagon signal more influential, and the liver increases glucose release to the bloodstream. Glucagon works through its receptor to raise cAMP, activating PKA, which promotes glycogenolysis and the expression of gluconeogenic enzymes like PEPCK and G6Pase. While cortisol can also boost hepatic glucose production, and adiponectin levels drop in obesity (which worsens insulin resistance), the classic and most direct trigger for hepatic glucose output in this context is increased glucagon signaling.